201 related articles for article (PubMed ID: 21455220)
1. Abl interconnects oncogenic Met and p53 core pathways in cancer cells.
Furlan A; Stagni V; Hussain A; Richelme S; Conti F; Prodosmo A; Destro A; Roncalli M; Barilà D; Maina F
Cell Death Differ; 2011 Oct; 18(10):1608-16. PubMed ID: 21455220
[TBL] [Abstract][Full Text] [Related]
2. c-Abl phosphorylation of Mdm2 facilitates Mdm2-Mdmx complex formation.
Waning DL; Lehman JA; Batuello CN; Mayo LD
J Biol Chem; 2011 Jan; 286(1):216-22. PubMed ID: 21081495
[TBL] [Abstract][Full Text] [Related]
3. STI571 reduces TRAIL-induced apoptosis in colon cancer cells: c-Abl activation by the death receptor leads to stress kinase-dependent cell death.
Huang DY; Chao Y; Tai MH; Yu YH; Lin WW
J Biomed Sci; 2012 Mar; 19(1):35. PubMed ID: 22462553
[TBL] [Abstract][Full Text] [Related]
4. Modulation of the p38 MAPK (mitogen-activated protein kinase) pathway through Bcr/Abl: implications in the cellular response to Ara-C.
Sánchez-Arévalo Lobo VJ; Aceves Luquero CI; Alvarez-Vallina L; Tipping AJ; Viniegra JG; Hernández Losa J; Parada Cobo C; Galán Moya EM; Gayoso Cruz J; Melo JV; Ramón y Cajal S; Sánchez-Prieto R
Biochem J; 2005 Apr; 387(Pt 1):231-8. PubMed ID: 15540985
[TBL] [Abstract][Full Text] [Related]
5. Pml and TAp73 interacting at nuclear body mediate imatinib-induced p53-independent apoptosis of chronic myeloid leukemia cells.
Liu JH; Liu CC; Yen CC; Gau JP; Wang WS; Tzeng CH
Int J Cancer; 2009 Jul; 125(1):71-7. PubMed ID: 19291793
[TBL] [Abstract][Full Text] [Related]
6. Imatinib reverses doxorubicin resistance by affecting activation of STAT3-dependent NF-κB and HSP27/p38/AKT pathways and by inhibiting ABCB1.
Sims JT; Ganguly SS; Bennett H; Friend JW; Tepe J; Plattner R
PLoS One; 2013; 8(1):e55509. PubMed ID: 23383209
[TBL] [Abstract][Full Text] [Related]
7. c-Abl activates p38 MAPK independently of its tyrosine kinase activity: Implications in cisplatin-based therapy.
Galan-Moya EM; Hernandez-Losa J; Aceves Luquero CI; de la Cruz-Morcillo MA; Ramírez-Castillejo C; Callejas-Valera JL; Arriaga A; Aranburo AF; Ramón y Cajal S; Silvio Gutkind J; Sánchez-Prieto R
Int J Cancer; 2008 Jan; 122(2):289-97. PubMed ID: 17893873
[TBL] [Abstract][Full Text] [Related]
8. Phosphorylation of the Mdm2 oncoprotein by the c-Abl tyrosine kinase regulates p53 tumor suppression and the radiosensitivity of mice.
Carr MI; Roderick JE; Zhang H; Woda BA; Kelliher MA; Jones SN
Proc Natl Acad Sci U S A; 2016 Dec; 113(52):15024-15029. PubMed ID: 27956626
[TBL] [Abstract][Full Text] [Related]
9. Requirement for Mdm2 in the survival effects of Bcr-Abl and interleukin 3 in hematopoietic cells.
Goetz AW; van der Kuip H; Maya R; Oren M; Aulitzky WE
Cancer Res; 2001 Oct; 61(20):7635-41. PubMed ID: 11606405
[TBL] [Abstract][Full Text] [Related]
10. Association between imatinib-resistant BCR-ABL mutation-negative leukemia and persistent activation of LYN kinase.
Wu J; Meng F; Kong LY; Peng Z; Ying Y; Bornmann WG; Darnay BG; Lamothe B; Sun H; Talpaz M; Donato NJ
J Natl Cancer Inst; 2008 Jul; 100(13):926-39. PubMed ID: 18577747
[TBL] [Abstract][Full Text] [Related]
11. Met acts through Abl to regulate p53 transcriptional outcomes and cell survival in the developing liver.
Furlan A; Lamballe F; Stagni V; Hussain A; Richelme S; Prodosmo A; Moumen A; Brun C; Del Barco Barrantes I; Arthur JS; Koleske AJ; Nebreda AR; Barilà D; Maina F
J Hepatol; 2012 Dec; 57(6):1292-8. PubMed ID: 22889954
[TBL] [Abstract][Full Text] [Related]
12. Imatinib mesylate induces cisplatin hypersensitivity in Bcr-Abl+ cells by differential modulation of p53 transcriptional and proapoptotic activity.
Skorta I; Oren M; Markwardt C; Gutekunst M; Aulitzky WE; van der Kuip H
Cancer Res; 2009 Dec; 69(24):9337-45. PubMed ID: 19934315
[TBL] [Abstract][Full Text] [Related]
13. The novel anticancer agent JNJ-26854165 is active in chronic myeloid leukemic cells with unmutated BCR/ABL and T315I mutant BCR/ABL through promoting proteosomal degradation of BCR/ABL proteins.
You L; Liu H; Huang J; Xie W; Wei J; Ye X; Qian W
Oncotarget; 2017 Jan; 8(5):7777-7790. PubMed ID: 27999193
[TBL] [Abstract][Full Text] [Related]
14. Loss of p53 impedes the antileukemic response to BCR-ABL inhibition.
Wendel HG; de Stanchina E; Cepero E; Ray S; Emig M; Fridman JS; Veach DR; Bornmann WG; Clarkson B; McCombie WR; Kogan SC; Hochhaus A; Lowe SW
Proc Natl Acad Sci U S A; 2006 May; 103(19):7444-9. PubMed ID: 16651519
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of c-Abl kinase activity renders cancer cells highly sensitive to mitoxantrone.
Alpay K; Farshchian M; Tuomela J; Sandholm J; Aittokallio K; Siljamäki E; Kallio M; Kähäri VM; Hietanen S
PLoS One; 2014; 9(8):e105526. PubMed ID: 25148385
[TBL] [Abstract][Full Text] [Related]
16. Identification of a novel p53-dependent activation pathway of STAT1 by antitumour genotoxic agents.
Youlyouz-Marfak I; Gachard N; Le Clorennec C; Najjar I; Baran-Marszak F; Reminieras L; May E; Bornkamm GW; Fagard R; Feuillard J
Cell Death Differ; 2008 Feb; 15(2):376-85. PubMed ID: 17992189
[TBL] [Abstract][Full Text] [Related]
17. ApoptomiRs expression modulated by BCR-ABL is linked to CML progression and imatinib resistance.
Ferreira AF; Moura LG; Tojal I; Ambrósio L; Pinto-Simões B; Hamerschlak N; Calin GA; Ivan C; Covas DT; Kashima S; Castro FA
Blood Cells Mol Dis; 2014; 53(1-2):47-55. PubMed ID: 24629639
[TBL] [Abstract][Full Text] [Related]
18. Aclacinomycin A sensitizes K562 chronic myeloid leukemia cells to imatinib through p38MAPK-mediated erythroid differentiation.
Lee YL; Chen CW; Liu FH; Huang YW; Huang HM
PLoS One; 2013; 8(4):e61939. PubMed ID: 23613979
[TBL] [Abstract][Full Text] [Related]
19. Synergistic effects of p53 activation via MDM2 inhibition in combination with inhibition of Bcl-2 or Bcr-Abl in CD34+ proliferating and quiescent chronic myeloid leukemia blast crisis cells.
Carter BZ; Mak PY; Mak DH; Ruvolo VR; Schober W; McQueen T; Cortes J; Kantarjian HM; Champlin RE; Konopleva M; Andreeff M
Oncotarget; 2015 Oct; 6(31):30487-99. PubMed ID: 26431162
[TBL] [Abstract][Full Text] [Related]
20. Immunohistochemical analysis of platelet-derived growth factor receptor-alpha, -beta, c-kit, c-abl, and arg proteins in glioblastoma: possible implications for patient selection for imatinib mesylate therapy.
Haberler C; Gelpi E; Marosi C; Rössler K; Birner P; Budka H; Hainfellner JA
J Neurooncol; 2006 Jan; 76(2):105-9. PubMed ID: 16205964
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]